Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 600 participants.
Also called NCT05465031
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 600 participants
- Registry
-
NCT05465031
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Poland
- Registry status
- Recruiting
Technical summary
Registry record NCT05465031. Randomized; triple masking; primary purpose prevention. Start 2024-04-17 (actual); primary completion 2027-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)
- Condition
- Breast Cancer
- Condition
- Neoplasm, Breast
- Condition
- Breast Diseases
- Condition
- Antihypertensive Agents
- Condition
- Sacubitril/Valsartan
- Condition
- Angiotensin II Type 1 Receptor Blockers
- Condition
- Angiotensin Receptor Antagonists
- Condition
- Molecular Mechanisms of Pharmacological Action
- Condition
- Heart Failure
- Condition
- Cardiac Toxicity
- Condition
- Cancer, Therapy-Related
- Condition
- Cancer Therapy-Related Cardiac Dysfunction
- Condition
- Cardiotoxicity
- Intervention (Drug)
- Sacubitril-valsartan
- Intervention (Drug)
- Placebo
- Lead sponsor
- Silesian Centre for Heart Diseases
- Collaborator
- Medical Research Agency, Poland
Record details
- Record id
cardio:ct-nct05465031- Content hash
e30d0411ecdc5b7932aa419a62c28d8c84e1b98487feaa9948ffa350a257d84e